Trial Profile

Effects of CYP3A Inhibition by Clarithromycin on the Pharmacokinetics of LY2835219 and Its Metabolites in Cancer Patients

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abemaciclib (Primary) ; Clarithromycin
Indications Solid tumours
Focus Pharmacokinetics
Sponsors Eli Lilly and Company

Most Recent Events

20 Apr 2016 Results presented at the 107th Annual Meeting of the American Association for Cancer Research.
18 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
12 Feb 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Feb 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com